Copyright
©The Author(s) 2021.
World J Clin Oncol. Aug 24, 2021; 12(8): 675-687
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.675
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.675
Table 4 Univariate analysis of variables related to the presence of additional disease on completion axillary lymph node dissection in the group of 79 cases with presence of only one macrometastatic sentinel lymph nodes
Additional metastatic lymph nodes, n = 79 | |
Age | |
< 40 | 50% |
≥ 40 | 28% |
≤ 15 mm | 85% |
> 15 mm | 49% |
Histologic type | |
Ductal carcinoma | 28% |
Lobular carcinoma | 50% |
Mucinous | 0 |
Tumor size | |
≤ 10 mm | 7% |
11-15 mm | 10% |
16-20 mm | 42% |
> 20 mm | 47% |
Grade | |
DCIS | 0 |
I | 18% |
II | 31% |
III | 45% |
Molecular subtype | |
Luminal A/B | 28% |
Basal | 55% |
HER2 | 0 |
- Citation: Herrero M, Ciérvide R, Calle-Purón ME, Valero J, Buelga P, Rodriguez-Bertos I, Benassi L, Montero A. Macrometastasis at selective lymph node biopsy: A practical going-for-the-one clinical scoring system to personalize decision making. World J Clin Oncol 2021; 12(8): 675-687
- URL: https://www.wjgnet.com/2218-4333/full/v12/i8/675.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i8.675